$XBI $67.70 | +5.17%
Table of Contents:
Covid Updates
$
Pipeline Updates
$FOLD +8.2% Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA source
$VYNE +0.3% VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform. source
$EVFM -7.4% Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®. source
$MBRX +1.5% Moleculin Receives Approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19. source
$CLSN -1.7% Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates. source
$ACRX -1.9% AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia. Source
$TPTX +9.0% Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy. source
$SCYX +0.5% SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting. source
$RLYB +6.1% Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi. source
$EVAX -5.9% Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02. source
$AKTX +5.3% Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology.source
$IMTX +3.0% Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors. source
$VERV +9.9% Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results. source
$CRVS +8.9% Corvus Pharmaceuticals Provides Program Updates at R&D Symposium. source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$PFE +1.7% Pfizer to Acquire Biohaven Pharmaceuticals. source
Posted by FS/JM
Kommentare